

Global Depression Treatment Market Research and Analysis, 2014-2020

<https://marketpublishers.com/r/G3DF8DD8BD7EN.html>

Date: April 2016

Pages: 140

Price: US\$ 3,495.00 (Single User License)

ID: G3DF8DD8BD7EN

Abstracts

Global depression treatment market is facing stiff decline. The market is expected to grow at low CAGR of 1% for the forecasted period of 2015-2020. One of the major factors for such low growth is rapid decline in the revenue of branded drug manufacturers and growing strength of generic drug manufacturers. The patent cliff has caused decline in revenues ranging from few million dollars to billions. The patent expiration and generic drug manufacturers gaining licences to manufacturers has forced many branded drug manufacturers to either stop their R&D or to reduce budgets. There are very limited number of new drugs in the pipeline. Branded drugs sales have declined from \$15 billion in 2006 to \$9 billion in 2013. Decline in revenues is majorly due to fall in the price of once expensive drugs by over 50-90 percent. Volume shipment are still high and increasing especially in emerging markets.

However, markets for therapies using medical devices such as Vagus nerve stimulation, deep brain stimulation and smart phones is rising. The devices market is expected to grow with a CAGR of 9.2%. Introduction of virtual reality in the treatment of disorders such as post-traumatic stress disorders is also driving the market.

North America and Europe currently are the leading markets. They make up for 70% of the total depression treatment market. The markets are driven by high awareness regarding depression and availability of drugs and therapies. However, the patent cliff has caused decline in the growth rates of the market. Asia Pacific will have the highest growth rate. Recently the discussion over effects of depression on the economies has been going on. Countries such as India, China and Japan are spending on the research of new treatment methods for treating depression. It is expected that new Asian companies could develop new branded drugs in the near future.

Contents

REPORT SUMMARY

- 1.1. RESEARCH METHODS AND TOOLS
- 1.2. MARKET BREAKDOWN
 - 1.2.1. BY SEGMENTS
 - 1.2.2. BY GEOGRAPHY
 - 1.2.3. BY STAKEHOLDERS
 - 1.2.4. EXCEPTIONS

MARKET OVERVIEW AND INSIGHTS

- 2.1. DEFINITION
- 2.2. GAP ANALYSIS
- 2.3. HISTORICAL ANALYSIS
- 2.4. CURRENT MARKET TRENDS
- 2.5. ANALYST INSIGHT
 - 2.5.1. KEY FINDINGS
 - 2.5.2. RECOMMENDATION
 - 2.5.3. CONCLUSION
- 2.6. REGULATION
 - 2.6.1. TAX LAWS
 - 2.6.1.1. UNITED STATES
 - 2.6.1.2. EUROPEAN UNION
 - 2.6.1.3. CHINA
 - 2.6.1.4. INDIA
 - 2.6.1.5. REST OF THE WORLD
 - 2.6.2. DRUG AND DEVICES REGULATIONS
 - 2.6.2.1. UNITED STATES
 - 2.6.2.2. EUROPEAN UNION
 - 2.6.2.3. CHINA
 - 2.6.2.4. INDIA
 - 2.6.2.5. REST OF THE WORLD
- 2.7. TYPE OF DEPRESSION DISORDERS
 - 2.7.1. MAJOR DEPRESSION
 - 2.7.2. BIPOLAR DEPRESSION
 - 2.7.3. SEASONAL AFFECTIVE DISORDER
 - 2.7.4. PSYCHOTIC DEPRESSION

- 2.7.5. POSTPARTUM DEPRESSION
- 2.7.6. ATYPICAL DEPRESSION
- 2.7.7. PERSISTENT DEPRESSIVE DISORDER

MARKET DETERMINANT

3.1. MOTIVATORS

- 3.1.1. HIGH PREVALENCE AND INCIDENCE OF MENTAL HEALTH DISORDERS
- 3.1.2. INCREASING AWARENESS RELATED TO MENTAL HEALTH DISORDERS
- 3.1.3. RISING MARKET FOR CHEAPER GENERIC DRUGS

3.2. RESTRAINT

- 3.2.1. HIGH COST OF THERAPIES
- 3.2.2. SIDE EFFECTS OF DEPRESSION DRUGS
- 3.2.3. EXPIRING PATENTS AND DRYING PIPELINES

3.3. OPPORTUNITY

- 3.3.1. EMERGING MARKETS
- 3.3.2. NEW THERAPIES SUCH AS VIRTUAL REALITY

PARENT MARKET ANALYSIS

MARKET SEGMENTATION

5.1. GLOBAL MARKET BY TYPE OF DEPRESSION RESEARCH AND ANALYSIS, 2014-2020

5.1.1. GLOBAL SEASONAL AFFECTIVE DISORDER (SAD) MARKET RESEARCH AND ANALYSIS, 2014-2020

5.1.2. GLOBAL MAJOR DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020

5.1.3. GLOBAL DYSTHYMIA DISORDER MARKET RESEARCH AND ANALYSIS, 2014-2020

5.1.4. GLOBAL POSTPARTUM DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020

5.1.5. GLOBAL ATYPICAL DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020

5.1.6. GLOBAL PSYCHOTIC DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020

5.1.7. GLOBAL BIPOLAR DISORDER MARKET RESEARCH AND ANALYSIS, 2014-2020

5.2. GLOBAL DEPRESSION DRUGS MARKET RESEARCH AND ANALYSIS,

2014-2020

5.2.1. GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS DRUGS
MARKET RESEARCH AND ANALYSIS, 2014-2020

5.2.1.1. GLOBAL FLUOXETINE (PROZAC) MARKET RESEARCH AND ANALYSIS,
2014-2020

5.2.1.2. GLOBAL SERTRALINE (ZOLOFT) MARKET RESEARCH AND ANALYSIS,
2014-2020

5.2.1.3. GLOBAL ESCITALOPRAM (LEXAPRO) MARKET RESEARCH AND
ANALYSIS, 2014-2020

5.2.1.4. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2014-2020

5.2.2. GLOBAL ATYPICAL ANTIDEPRESSANTS MARKET RESEARCH AND
ANALYSIS, 2014-2020

5.2.2.1. GLOBAL BUPROPION (WELLBUTRIN) MARKET RESEARCH AND
ANALYSIS, 2014-2020

5.2.2.2. GLOBAL DULOXETINE (CYMBALTA) MARKET RESEARCH AND
ANALYSIS, 2014-2020

5.2.2.3. GLOBAL VENLAFAXINE (EFFEXOR) MARKET RESEARCH AND
ANALYSIS, 2014-2020

5.2.2.4. GLOBAL DESVENLAFEXINE (PRISTIQ) MARKET RESEARCH AND
ANALYSIS, 2014-2020

5.2.2.5. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2014-2020

5.2.3. GLOBAL TRICYCLIC ANTIDEPRESSANTS MARKET RESEARCH AND
ANALYSIS, 2014-2020

5.3. GLOBAL DEPRESSION TREATMENT DEVICES MARKET RESEARCH AND
ANALYSIS, 2014-2020

5.3.1. GLOBAL TRANSCRANIAL MAGNETIC STIMULATOR MARKET RESEARCH
AND ANALYSIS, 2014-2020

5.3.2. GLOBAL DEEP BRAIN STIMULATOR MARKET RESEARCH AND ANALYSIS,
2014-2020

5.3.3. GLOBAL VIRTUAL REALITY THERAPY MARKET RESEARCH AND
ANALYSIS, 2014-2020

5.3.4. GLOBAL VAGUS NERVE SIMULATOR MARKET RESEARCH AND
ANALYSIS, 2014-2020

5.3.5. GLOBAL SMART PHONE APPLICATIONS MARKET RESEARCH AND
ANALYSIS, 2014-2020

5.3.6. GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2014-2020

COMPETITIVE LANDSCAPE

6.1. MARKET SHARE ANALYSIS

6.2. KEY COMPANY ANALYSIS

REGIONAL ANALYSIS

7.1. NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020

7.1.1. UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020

7.1.2. CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020

7.2. EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020

7.2.1. WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020

7.2.2. ROE MARKET RESEARCH AND ANALYSIS, 2014-2020

7.3. ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020

7.3.1. INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020

7.3.2. CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020

7.3.3. JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020

7.3.4. ROAPAC MARKET RESEARCH AND ANALYSIS, 2014-2020

7.4. REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020

COMPANY PROFILES

8.1. PFIZER

8.1.1. INTRODUCTION

8.1.2. PRODUCT PORTFOLIO

8.1.3. RECENT ACTIVITIES

8.1.4. SWOT

8.2. GLAXOSMITHKLINE

8.2.1. INTRODUCTION

8.2.2. PRODUCT PORTFOLIO

8.2.3. RECENT ACTIVITIES

8.2.4. SWOT

8.3. FOREST LABS

8.3.1. INTRODUCTION

8.3.2. PRODUCT PORTFOLIO

8.3.3. RECENT ACTIVITIES

8.3.4. SWOT

8.4. SUN PHARMA

8.4.1. INTRODUCTION

8.4.2. PRODUCT PORTFOLIO

8.4.3. RECENT ACTIVITIES

- 8.4.4. SWOT
- 8.5. ELI LILY AND COMPANY
 - 8.5.1. INTRODUCTION
 - 8.5.2. PRODUCT PORTFOLIO
 - 8.5.3. RECENT ACTIVITIES
 - 8.5.4. SWOT
- 8.6. H. LUNDBECK A/S
 - 8.6.1. INTRODUCTION
 - 8.6.2. PRODUCT PORTFOLIO
 - 8.6.3. RECENT ACTIVITIES
 - 8.6.4. SWOT
- 8.7. JOHNSON AND JOHNSON
 - 8.7.1. INTRODUCTION
 - 8.7.2. PRODUCT PORTFOLIO
 - 8.7.3. RECENT ACTIVITIES
 - 8.7.4. SWOT
- 8.8. MERCK AND CO.
 - 8.8.1. INTRODUCTION
 - 8.8.2. PRODUCT PORTFOLIO
 - 8.8.3. RECENT ACTIVITIES
 - 8.8.4. SWOT
- 8.9. ASTRAZENECA
 - 8.9.1. INTRODUCTION
 - 8.9.2. PRODUCT PORTFOLIO
 - 8.9.3. RECENT ACTIVITIES
 - 8.9.4. SWOT
- 8.10. NOVARTIS
 - 8.10.1. INTRODUCTION
 - 8.10.2. PRODUCT PORTFOLIO
 - 8.10.3. RECENT ACTIVITIES
 - 8.10.4. SWOT
- 8.11. SANOFI-AVENTIS
 - 8.11.1. INTRODUCTION
 - 8.11.2. PRODUCT PORTFOLIO
 - 8.11.3. RECENT ACTIVITIES
 - 8.11.4. SWOT
- 8.12. TEVA PHARMACEUTICALS
 - 8.12.1. INTRODUCTION
 - 8.12.2. PRODUCT PORTFOLIO

- 8.12.3. RECENT ACTIVITIES
- 8.12.4. SWOT
- 8.13. OTSUKA PHARMACEUTICALS
 - 8.13.1. INTRODUCTION
 - 8.13.2. PRODUCT PORTFOLIO
 - 8.13.3. RECENT ACTIVITIES
 - 8.13.4. SWOT
- 8.14. TAKEDA PHARMACEUTICALS
 - 8.14.1. INTRODUCTION
 - 8.14.2. PRODUCT PORTFOLIO
 - 8.14.3. RECENT ACTIVITIES
 - 8.14.4. SWOT
- 8.15. TEVA PHARMACEUTICALS
 - 8.15.1. INTRODUCTION
 - 8.15.2. PRODUCT PORTFOLIO
 - 8.15.3. RECENT ACTIVITIES
 - 8.15.4. SWOT
- 8.16. CYBERONICS INC. (LIVANOVA)
 - 8.16.1. INTRODUCTION
 - 8.16.2. PRODUCT PORTFOLIO
 - 8.16.3. RECENT ACTIVITIES
 - 8.16.4. SWOT
- 8.17. ALEVI NEUROTHERAPEUTICS
 - 8.17.1. INTRODUCTION
 - 8.17.2. PRODUCT PORTFOLIO
 - 8.17.3. RECENT ACTIVITIES
 - 8.17.4. SWOT
- 8.18. BRISTOL MYERS SQUIBB
 - 8.18.1. INTRODUCTION
 - 8.18.2. PRODUCT PORTFOLIO
 - 8.18.3. RECENT ACTIVITIES
 - 8.18.4. SWOT
- 8.19. MAYO CLINIC
 - 8.19.1. INTRODUCTION
 - 8.19.2. PRODUCT PORTFOLIO
 - 8.19.3. RECENT ACTIVITIES
 - 8.19.4. SWOT
- 8.20. NEUROSTAR
 - 8.20.1. INTRODUCTION

8.20.2. PRODUCT PORTFOLIO

8.20.3. RECENT ACTIVITIES

8.20.4. SWOT

List Of Tables

LIST OF TABLES

TABLE # 1 GLOBAL MARKET BY TYPE OF DEPRESSION RESEARCH AND ANALYSIS, 2014-2020

TABLE # 2 GLOBAL SEASONAL AFFECTIVE DISORDER (SAD) MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 3 GLOBAL UNI-POLAR OR MAJOR DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 4 GLOBAL DYSTHYMIA OR DYSTHYMIA DISORDER MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 5 GLOBAL POSTPARTUM DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 6 GLOBAL ATYPICAL DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 7 GLOBAL PSYCHOTIC DEPRESSION MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 8 GLOBAL BIPOLAR DISORDER MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 9 GLOBAL DEPRESSION DRUGS MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 10 GLOBAL SELECTIVE SEROTONIN REUPTAKE INHIBITORS DRUGS MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 11 GLOBAL FLUOXETINE (PROZAC) MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 12 GLOBAL SERTRALINE (ZOLOFT) MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 13 GLOBAL ESCITALOPRAM (LEXAPRO) MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 14 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 15 GLOBAL ATYPICAL ANTIDEPRESSANTS MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 16 GLOBAL BUPROPION (WELLBUTRIN) MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 17 GLOBAL DULOXETINE (CYMBALTA) MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 18 GLOBAL VENLAFAXINE (EFFEXOR) MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 19 GLOBAL DESVENLAFEXINE (PRISTIQ) MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 20 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 21 GLOBAL TRICYCLIC ANTIDEPRESSANTS MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 22 GLOBAL DEPRESSION TREATMENT DEVICES MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 23 GLOBAL TRANSCRANIAL MAGNETIC STIMULATOR MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 24 GLOBAL DEEP BRAIN STIMULATOR MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 25 GLOBAL VIRTUAL REALITY THERAPY MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 26 GLOBAL VAGUS NERVE SIMULATOR MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 27 GLOBAL SMART PHONE APPLICATIONS MARKET RESEARCH AND ANALYSIS, 2014-2020

TABLE # 28 GLOBAL OTHERS MARKET RESEARCH AND ANALYSIS, 2014-2020

List Of Figures

LIST OF FIGURES

FIGURE # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020

FIGURE # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020

FIGURE # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020

FIGURE # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020

FIGURE # 5 WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020

FIGURE # 6 ROE MARKET RESEARCH AND ANALYSIS, 2014-2020

FIGURE # 7 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020

FIGURE # 8 INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020

FIGURE # 9 CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020

FIGURE # 10 JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020

FIGURE # 11 ROAPAC MARKET RESEARCH AND ANALYSIS, 2014-2020

FIGURE # 12 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS,
2014-2020

COMPANIES MENTIONED

1. PFIZER
2. GLAXOSMITHKLINE
3. FOREST LABS
4. SUN PHARMA
5. ELI LILY AND COMPANY
6. H. LUNDBECK A/S
7. JOHNSON AND JOHNSON
8. MERCK AND CO.
9. ASTRAZENECA
10. NOVARTIS
11. SANOFI-AVENTIS
12. TEVA PHARMACEUTICALS
13. OTSUKA PHARMACEUTICALS
14. TAKEDA PHARMACEUTICALS
15. TEVA PHARMACEUTICALS
16. CYBERONICS INC. (LIVANOVA)
17. ALEVI NEUROTHERAPEUTICS
18. BRISTOL MYERS SQUIBB
19. MAYO CLINIC

20. NEUROSTAR

I would like to order

Product name: Global Depression Treatment Market Research and Analysis, 2014-2020

Product link: <https://marketpublishers.com/r/G3DF8DD8BD7EN.html>

Price: US\$ 3,495.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G3DF8DD8BD7EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970